FSD Pharma Inc. Board Approves Share Repurchase Program

FSD Pharma HUGE, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is repurchasing up to 2 million company shares. The company announced that its board of directors had approved the move, which allows the company to purchase the shares over the next year at prevailing market prices. The repurchasing plan, which begins on Jan. 4, 2022, and ends on Dec. 30, 2022 (unless the company ends the program earlier), allows FSD Pharma to use its excess cash reserves to strategically return value to shareholders.

The plan calls for the company to purchase up to 2 million subordinate voting shares, which is approximately 5% of the company’s issued and outstanding subordinate voting shares. “FSD Pharma is focused on the advancement of its drug candidates toward the clinic,” said FSD Pharma interim CEO Anthony Durkacz in the press release. “However, with over $39.3 million in cash and cash equivalents on our balance sheet as of Sept. 30, 2021, we recognize there may be a strategic opportunity to enhance shareholder value without compromising our ambitious growth plans. We believe that our stock is significantly undervalued. This will allow us to continue investing in our future, while, at the same time, also investing in the exceptional value that our own shares represent.”

To view the full press releases, visit https://ibn.fm/bn4k2

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA, formerly called FSD-201. Lucid Psycheceuticals Inc. is a wholly owned subsidiary focused on the research and development of FSD Pharma’s lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information about the company, please visit www.FSDPharma.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content was purely for informational purposes only and not intended to be investing advice.

Image Sourced from Pixabay